Anti-Mullerian Hormone (AMH)

Anti-Mullerian Hormone (AMH) is a protein hormone produced by the granulosa cells of developing ovarian follicles. It provides a snapshot of a woman's ovarian reserve — the approximate number of eggs remaining in the ovaries. Unlike many reproductive hormones, AMH levels remain relatively stable throughout the menstrual cycle, making it convenient to test at any point.

AMH is produced by small antral follicles and pre-antral follicles, meaning it reflects the pool of follicles that have begun developing but have not yet been selected for ovulation. It does not measure egg quality, only quantity.

In men, AMH is produced by the Sertoli cells of the testes and plays a role during foetal development. In adult men, AMH levels are generally low and less clinically significant, though they may be useful in assessing testicular function in certain situations.

AMH is one of the most valuable biomarkers for women considering their fertility timeline. As the ovarian reserve naturally declines with age, AMH provides an objective measure of where you stand relative to others of your age. This information can be empowering for family planning decisions.

Beyond fertility, AMH has relevance to broader health. Very low AMH may indicate early ovarian ageing, while very high AMH can be associated with polycystic ovary syndrome (PCOS). Some research suggests that AMH may also have links to cardiovascular health and bone density, though these associations are still being explored.

For longevity-focused health monitoring, AMH offers insight into reproductive ageing, which can serve as a proxy for certain aspects of biological ageing. Understanding your ovarian reserve early allows for informed decisions about fertility preservation if desired.

Anti-Mullerian hormone (AMH) is a marker of ovarian reserve — the number of remaining eggs in the ovaries. Unlike most other hormones, AMH is relatively stable across the menstrual cycle, making it convenient to test at any time. AMH declines with age and provides an estimate of reproductive potential, though it does not predict natural fertility on its own.

While wearable devices cannot measure or predict AMH levels, general health and fitness tracked by your wearable support reproductive health. Regular moderate exercise, visible in your step counts and active minutes, is associated with better reproductive outcomes. Conversely, extreme exercise with energy deficiency, identifiable through very high training loads without adequate caloric intake, can impair reproductive function regardless of AMH levels.

For women monitoring fertility, wearable cycle tracking features complement AMH testing by providing continuous data on cycle regularity, ovulation timing (via temperature shifts), and luteal phase length. This combined approach of periodic blood biomarkers and continuous wearable data gives the most comprehensive picture of reproductive health.